Contrary melanoma‑associated antigen‑A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinoma

Hartmann,Stefan; Brisam,Muna; Rauthe,Stephan; Driemel,Oliver; Brands,Roman C.; Rosenwald,Andreas; Kübler,Alexander C.; Müller‑Richter,Urs D. A.

doi:10.3892/ol.2016.4945

Contrary melanoma‑associated antigen‑A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinoma

Authors:
- Stefan Hartmann
- Muna Brisam
- Stephan Rauthe
- Oliver Driemel
- Roman C. Brands
- Andreas Rosenwald
- Alexander C. Kübler
- Urs D. A. Müller‑Richter
View Affiliations

Affiliations: Department of Oral and Maxillofacial Plastic Surgery, University Hospital Würzburg, D‑97070 Würzburg, Germany, Institute of Pathology and Comprehensive Cancer Center Mainfranken, University of Würzburg, D‑97080 Würzburg, Germany, Department of Oral and Maxillofacial Plastic Surgery, University Hospital Rostock, D-18057 Rostock, Germany
Published online on: August 3, 2016 https://doi.org/10.3892/ol.2016.4945
Pages: 2942-2947

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is a growing body of evidence indicating that several melanoma‑associated antigen‑A (MAGE‑A) subgroups contribute to the malignancy of head and neck cancer. The present study retrospectively analyzed the expression of all known MAGE‑A subgroups in the tumor front and center of 38 head and neck cancer patients (Union for International Cancer Control stage I or IV) by immunohistochemistry. MAGE‑A1, ‑A6, ‑A8, ‑A9 and ‑A11 were expressed at significantly higher levels at the tumor front of stage IV specimens compared with the tumor front of stage I specimens. In stage I cancer, the tumor center and front ratio (C/F ratio) for each subgroup was >1.0. In stage IV cancer, the C/F ratio was <1.0 in 9/11 subgroups. The most significant change in the expression pattern was observed for MAGE‑A11. These results indicated that there is a marked alteration and shift to the invasive front of almost all MAGE‑A subgroups, but particularly MAGE‑A11, during the progression of head and neck squamous cell carcinoma.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, LortetTieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Hamoir M, Schmitz S and Gregoire V: The role of neck dissection in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol. 15:611–624. 2014. View Article : Google Scholar : PubMed/NCBI
4	van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
5	AbdElsalam EA and Ismaeil NA: Melanoma-associated antigen genes: A new trend to predict the prognosis of breast cancer patients. Med Oncol. 31:2852014. View Article : Google Scholar : PubMed/NCBI
6	Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, et al: Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer. 135:1142–1152. 2014. View Article : Google Scholar : PubMed/NCBI
7	Li G, Song P and Zhang B: Expression and significance of MAGE genes in human lung cancer. Zhongguo Fei Ai Za Zhi. 16:308–313. 2013.PubMed/NCBI
8	Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M and Schneider C: MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA. 103:11160–11165. 2006. View Article : Google Scholar : PubMed/NCBI
9	Hartmann S, Kriegebaum U, Küchler N, Brands RC, Linz C, Kübler AC and Müller-Richter UD: Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells. Clin Oral Investig. 18:189–197. 2014. View Article : Google Scholar : PubMed/NCBI
10	Hartmann S, Kriegebaum U, Küchler N, Lessner G, Brands RC, Linz C, Schneider T, Kübler AC and Müller-Richter UD: Efficacy of cetuximab and panitumumab in oral squamous cell carcinoma cell lines: Prognostic value of MAGE-A subgroups for treatment success. J Craniomaxillofac Surg. 41:623–629. 2013. View Article : Google Scholar : PubMed/NCBI
11	Xia LP, Xu M, Chen Y and Shao WW: Expression of MAGE-A11 in breast cancer tissues and its effects on the proliferation of breast cancer cells. Mol Med Rep. 7:254–258. 2013.PubMed/NCBI
12	Minges JT, Su S, Grossman G, Blackwelder AJ, Pop EA, Mohler JL and Wilson EM: Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers. J Biol Chem. 288:1939–1952. 2013. View Article : Google Scholar : PubMed/NCBI
13	Ries J, Agaimy A, Vairaktaris E, Gorecki P, Neukam FW, Strassburg LH and Nkenke E: Detection of MAGE-A expression predicts malignant transformation of oral leukoplakia. Cancer Invest. 30:495–502. 2012. View Article : Google Scholar : PubMed/NCBI
14	Krauss E, Rauthe S, Gattenlöhner S, Reuther T, Kochel M, Kriegebaum U, Kübler AC and Müller-Richter UD: MAGE-A antigens in lesions of the oral mucosa. Clin Oral Investig. 15:315–320. 2011. View Article : Google Scholar : PubMed/NCBI
15	Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG and Morrow M: AJCC cancer staging manual. 6th edition. Springer; New York: 2002, View Article : Google Scholar
16	Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
17	Hildebrand LC, Carvalho AL, Lauxen IS, Nör JE, Cerski CT and Sant'Ana Filho M: Spatial distribution of cancer stem cells in head and neck squamous cell carcinomas. J Oral Pathol Med. 43:499–506. 2014. View Article : Google Scholar : PubMed/NCBI
18	Lindberg P, Larsson A and Nielsen BS: Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. Int J Cancer. 118:2948–2956. 2006. View Article : Google Scholar : PubMed/NCBI
19	Ries J, SchultzeMosgau S, Neukam F, Diebel E and Wiltfang J: Investigation of the expression of melanoma antigen-encoding genes (MAGE-A1 to-A6) in oral squamous cell carcinomas to determine potential targets for gene-based cancer immunotherapy. Int J Oncol. 26:817–824. 2005.PubMed/NCBI
20	van den Brand M, Takes RP, Blokpoel-deRuyter M, Slootweg PJ and van Kempen LC: Activated leukocyte cell adhesion molecule expression predicts lymph node metastasis in oral squamous cell carcinoma. Oral Oncol. 46:393–398. 2010. View Article : Google Scholar : PubMed/NCBI
21	MullerRichter UD, Dowejko A, Reuther T, Kleinheinz J, Reichert TE and Driemel O: Analysis of expression profiles of MAGE-A antigens in oral squamous cell carcinoma cell lines. Head Face Med. 5:102009. View Article : Google Scholar : PubMed/NCBI
22	Voskens CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, Taylor R, Wolf J, Suntharalingam M, Gastman B, et al: Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck. 34:1734–1746. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zandberg DP, Rollins S, Goloubeva O, Morales RE, Tan M, Taylor R, Wolf JS, Schumaker LM, Cullen KJ, Zimrin A, et al: A phase I dose escalation trial of MAGE-A3-and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). Cancer Immunol Immunother. 64:367–379. 2015. View Article : Google Scholar : PubMed/NCBI
24	Han L, Jiang B, Wu H, Zhang S and Lu X: Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 7:6734–6742. 2014.PubMed/NCBI
25	Hartmann S, Brands RC, Küchler N, Fuchs A, Linz C, Kübler AC and Müller-Richter UD: Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer. Oncol Lett. 10:1211–1217. 2015.PubMed/NCBI
26	Wilson EM: Androgen receptor molecular biology and potential targets in prostate cancer. Ther Adv Urol. 2:105–117. 2010. View Article : Google Scholar : PubMed/NCBI